Professor Marja-Riitta Taskinen discusses results of 40 years of clinical trials investigating the effects of fibrates on cardiovascular outcomes, including in patients with dyslipidaemia and type 2 diabetes. She concludes that fenofibrate has macro- and microvascular benefits and is a useful, cost-effective option for treating raised triglycerides in patients with type 2 diabetes taking statins, though treatment should be tailored to those most likely to benefit.
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
